| Q26749571 | A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment |
| Q37373680 | A(2B) adenosine receptors in immunity and inflammation. |
| Q36218394 | A(₂B)AR expression in non-immune cells plays an important role in the development of murine colitis |
| Q36410586 | A2B adenosine receptor activation switches differentiation of bone marrow cells to a CD11c(+)Gr-1(+) dendritic cell subset that promotes the Th17 response |
| Q28087576 | A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy |
| Q34280067 | AMP affects intracellular Ca2+ signaling, migration, cytokine secretion and T cell priming capacity of dendritic cells |
| Q59341050 | ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity |
| Q28074665 | Adenosine A2B Receptor: From Cell Biology to Human Diseases |
| Q30416420 | Adenosine A2B receptor blockade slows growth of bladder and breast tumors |
| Q90004707 | Adenosine Blockage in Tumor Microenvironment and Improvement of Cancer Immunotherapy |
| Q99708886 | Adenosine Signaling in Autoimmune Disorders |
| Q39148961 | Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. |
| Q85820879 | Adenosine and cAMP signalling skew human dendritic cell differentiation towards a tolerogenic phenotype with defective CD8(+) T-cell priming capacity |
| Q36575938 | Adenosine and gastrointestinal inflammation. |
| Q36821572 | Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? |
| Q37309945 | Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages |
| Q50086989 | Adenosine metabolism, immunity and joint health. |
| Q37948081 | Adenosine receptor targeting in health and disease |
| Q47690581 | Adenosine receptors differentially regulate type 2 cytokine production by IL-33-activated bone marrow cells, ILC2s, and macrophages |
| Q59354766 | Adenosine signaling and adenosine deaminase regulation of immune responses: impact on the immunopathogenesis of HIV infection |
| Q38358000 | Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations |
| Q35566772 | Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells |
| Q90704170 | Adenosinergic signaling as a target for natural killer cell immunotherapy |
| Q35683809 | An A2B Adenosine Receptor Agonist Promotes Th17 Autoimmune Responses in Experimental Autoimmune Uveitis (EAU) via Dendritic Cell Activation |
| Q33667612 | Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis |
| Q34988261 | Anti-inflammatory or proinflammatory effect of an adenosine receptor agonist on the Th17 autoimmune response is inflammatory environment-dependent |
| Q38132055 | Antiangiogenic therapy improves the antitumor effect of adoptive cell immunotherapy by normalizing tumor vasculature |
| Q28386225 | Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis |
| Q33868549 | Attenuation of chronic pulmonary inflammation in A2B adenosine receptor knockout mice |
| Q93179110 | Augmenting the therapeutic efficacy of adenosine against pancreatic cancer by switching the Akt/p21-dependent senescence to apoptosis |
| Q37157425 | Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors |
| Q37448109 | Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. |
| Q89663687 | CD73 Blockade Promotes Dendritic Cell Infiltration of Irradiated Tumors and Tumor Rejection |
| Q99706828 | CD73 contributes to anti-inflammatory properties of afferent lymphatic endothelial cells in humans and mice |
| Q35015717 | CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice |
| Q37641666 | CD73 is associated with poor prognosis in HNSCC. |
| Q94464383 | CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers |
| Q34739851 | Cholera toxin impairs the differentiation of monocytes into dendritic cells, inducing professional antigen-presenting myeloid cells |
| Q51706009 | Circulating mycobacterial-reactive CD4+ T cells with an immunosuppressive phenotype are higher in active tuberculosis than latent tuberculosis infection. |
| Q28395157 | Coordinated regulation of myeloid cells by tumours |
| Q37893080 | Cyclic nucleotides and phosphodiesterases in monocytic differentiation |
| Q34719397 | Deconstructing tick saliva: non-protein molecules with potent immunomodulatory properties. |
| Q36188900 | Deletion of TGF-β signaling in myeloid cells enhances their anti-tumorigenic properties. |
| Q64085682 | Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity |
| Q64094669 | Downregulation of CD73 associates with T cell exhaustion in AML patients |
| Q38023121 | ENTPD1/CD39 is a promising therapeutic target in oncology |
| Q36021197 | Expression of adenosine receptors in monocytes from patients with bronchial asthma. |
| Q38206399 | Extracellular adenosine metabolism in immune cells in melanoma |
| Q37775889 | Extracellular adenosine triphosphate and adenosine in cancer. |
| Q33878542 | Extracellular adenosine-mediated modulation of regulatory T cells |
| Q61651632 | Generation of anti-inflammatory adenosine byleukocytes is regulated by TGF-β |
| Q36861242 | HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism |
| Q84014638 | High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation |
| Q33750869 | Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors |
| Q92572055 | Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy |
| Q50217783 | Immune Cell Metabolism in Tumor Microenvironment |
| Q36024656 | Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). |
| Q34038901 | Immunity, inflammation and cancer: a leading role for adenosine |
| Q38215678 | Immunoregulatory activity of adenosine and its role in human cancer progression |
| Q90172862 | Immunosurveillance of cancer cell stress |
| Q37527800 | Immunotherapeutic strategies in kidney cancer--when TKIs are not enough |
| Q37766241 | Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target. |
| Q53146138 | Inflammation related responses of intestinal cells to plum and cabbage digesta with differential carotenoid and polyphenol profiles following simulated gastrointestinal digestion. |
| Q37287000 | Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action |
| Q64953266 | Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma. |
| Q37891130 | Innate immunity in allergic disease |
| Q38685844 | Interaction between saliva's adenosine and tick parasitism: effects on feeding and reproduction. |
| Q36731575 | Investigational A₃ adenosine receptor targeting agents |
| Q58824952 | Leishmania amazonensisimpairs DC function by inhibiting CD40 expression via A2Badenosine receptor activation |
| Q30428503 | Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans |
| Q38336989 | Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects |
| Q52763883 | Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease? |
| Q64088355 | Metabolic Control of Dendritic Cell Functions: Digesting Information |
| Q89388911 | Metabolic Stress in the Immune Function of T Cells, Macrophages and Dendritic Cells |
| Q27011306 | Metabolic influences that regulate dendritic cell function in tumors |
| Q39030292 | Metabolites: deciphering the molecular language between DCs and their environment. |
| Q28393614 | Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics |
| Q28072712 | Monitoring of the Immune Dysfunction in Cancer Patients |
| Q30433245 | Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology |
| Q46026307 | Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. |
| Q36296504 | Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy |
| Q28069621 | Myeloid cells in the tumor microenvironment: Role of adenosine |
| Q42094877 | Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment |
| Q36413809 | Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model |
| Q37229864 | Neonatal pneumococcal conjugate vaccine immunization primes T cells for preferential Th2 cytokine expression: a randomized controlled trial in Papua New Guinea |
| Q35368022 | Nucleosides from Phlebotomus papatasi salivary gland ameliorate murine collagen-induced arthritis by impairing dendritic cell functions. |
| Q35300310 | Nucleosides present on phlebotomine saliva induce immunossuppression and promote the infection establishment. |
| Q92082162 | Nutritional Modulation of Immune and Central Nervous System Homeostasis: The Role of Diet in Development of Neuroinflammation and Neurological Disease |
| Q28389236 | Orchestration of angiogenesis by immune cells |
| Q46560126 | Pediatric tolerogenic DCs expressing CD4 and immunoglobulin-like transcript receptor (ILT)-4 secrete IL-10 in response to Fc and adenosine. |
| Q38058320 | Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape |
| Q41342104 | Prognositic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review |
| Q38847756 | Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies |
| Q36729107 | Protumor activities of the immune response: insights in the mechanisms of immunological shift, oncotraining, and oncopromotion. |
| Q38753350 | Purinergic regulation of the immune system |
| Q38263455 | Purinergic signalling and immune cells |
| Q39331944 | Purinergic signalling links mechanical breath profile and alveolar mechanics with the pro-inflammatory innate immune response causing ventilation-induced lung injury. |
| Q26823216 | Regulation generation: the suppressive functions of human regulatory T cells |
| Q37876538 | Regulation of leukocyte function by adenosine receptors |
| Q36070200 | Regulation of macrophage function by adenosine |
| Q38546386 | Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis |
| Q89622533 | Reverting Immune Suppression to Enhance Cancer Immunotherapy |
| Q37405416 | Role of JunB in adenosine A2B receptor-mediated vascular endothelial growth factor production. |
| Q28393883 | Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors |
| Q92538625 | Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion |
| Q37108355 | Role of adenosine A(2B) receptors in inflammation |
| Q34123206 | Role of adenosine A2B receptor signaling in contribution of cardiac mesenchymal stem-like cells to myocardial scar formation. |
| Q42856686 | Role of the P2Y12 Receptor in the Modulation of Murine Dendritic Cell Function by ADP |
| Q34277485 | Roles of the adenosine receptor and CD73 in the regulatory effect of γδ T cells |
| Q90655148 | Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers |
| Q59335796 | Single-Cell Transcriptomics in Cancer Immunobiology: The Future of Precision Oncology |
| Q47135720 | Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma |
| Q35814020 | TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms |
| Q39125149 | Targeting A2 adenosine receptors in cancer |
| Q60921609 | Targeting Adenosine Receptor Signaling in Cancer Immunotherapy |
| Q93062525 | Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function |
| Q98164583 | Targeting CD39 in cancer |
| Q55330380 | Targeting adenosine for cancer immunotherapy. |
| Q46140918 | Targeting immunosuppressive adenosine in cancer |
| Q90529594 | Targeting of G-protein coupled receptors in sepsis |
| Q36620552 | Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer |
| Q30434114 | The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells |
| Q30426440 | The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6 |
| Q92713792 | The Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function |
| Q60048481 | The Regulatory Status Adopted by Lymph Node Dendritic Cells and T Cells During Healthy Aging Is Maintained During Cancer and May Contribute to Reduced Responses to Immunotherapy |
| Q49194479 | The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy |
| Q96230894 | The adenosine pathway in immuno-oncology |
| Q37524827 | The adenosinergic immunomodulatory drugs |
| Q52641713 | The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. |
| Q38197098 | The colon cancer stem cell microenvironment holds keys to future cancer therapy |
| Q39161005 | The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets |
| Q38666253 | The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. |
| Q34307284 | The resurgence of A2B adenosine receptor signaling |
| Q39032617 | The role of Th17-associated cytokines in the pathogenesis of experimental autoimmune uveitis (EAU). |
| Q34003164 | The roles of CD73 in cancer |
| Q91840488 | The yin and yang functions of extracellular ATP and adenosine in tumor immunity |
| Q37079141 | Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy |
| Q96167005 | Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints |
| Q38777795 | Tumor-derived factors modulating dendritic cell function |
| Q98185640 | Tumorigenesis and Progression As A Consequence of Hypoxic TME：A Prospective View upon Breast Cancer Therapeutic Targets |
| Q58780996 | Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression |
| Q37931979 | cAMP during HIV infection: friend or foe? |